[
    "{\"step_by_step_thinking\": \"Based on the relevant documents, serum can be used for analyzing the EGFR mutation status in patients with advanced non-small cell lung cancer. Document [0] states that EGFR mutation status in serum samples was consistent with the mutation status in tumor samples in 87.7% of cases. Document [2] also supports this, showing that EGFR mutation status in serum was detected in 33.8% of NSCLC patients and was associated with improved drug efficacy. Therefore, the answer is A. yes.\", \"answer_choice\": \"A\"}"
]